# Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection

> **NCT03859128** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Shanghai Junshi Bioscience Co., Ltd.** · enrollment: 402 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** TORIPALIMAB INJECTION(JS001 )

## Key facts

- **NCT ID:** NCT03859128
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-03-05
- **Primary completion:** 2023-04-18
- **Final completion:** 2023-08-01
- **Target enrollment:** 402 (ESTIMATED)
- **Last updated:** 2023-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03859128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03859128, "Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03859128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*